Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GCWB212
- Development stage
- Preclinical
- Lead developer
- GC Wellbeing
- Modality
- Small Molecules
01
Overview
GCWB212 is an investigational small molecule hepatoprotectant being developed by GC Green Cross Wellbeing (formerly Green Cross Wellbeing) for the treatment of chronic liver disease. The drug is currently in clinical development in South Korea. While it is positioned within the company's pipeline alongside other liver-directed therapies, its precise molecular target and mechanism of action remain undefined in public disclosures.
Beyond the preview
Go deeper on GCWB212.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GCWB212.